International Aids Vaccine Initiative
A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein BG505 SOSIP.GT1.1 Gp140 Vaccine, Adjuvanted in Healthy, HIV-uninfected Adults
- Conditions
- HIV Infections
- Interventions
- Biological: Placebo
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- International AIDS Vaccine Initiative
- Target Recruit Count
- 48
- Registration Number
- NCT04224701
- Locations
- 🇺🇸
George Washington University, Washington, District of Columbia, United States
🇺🇸Rockefeller University, New York, New York, United States
🇳🇱The Amsterdam University Medical Centers, Amsterdam, Netherlands
Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults
- Conditions
- HIV-1-infection
- Interventions
- Biological: 10-1074-LS-JBiological: Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 2Biological: Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 1Biological: Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 3Biological: Combination 3BNC117-LS-J and 10-1074-LS-JBiological: Placebo
- First Posted Date
- 2019-11-22
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- International AIDS Vaccine Initiative
- Target Recruit Count
- 225
- Registration Number
- NCT04173819
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸The Rockefeller University, New York, New York, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
A Phase 1/2a Study of PGT121, VRC07-523LS and PGDM1400 Monoclonal Antibodies in HIV-uninfected and HIV-infected Adults
- Conditions
- HIV/AIDS
- First Posted Date
- 2018-10-26
- Last Posted Date
- 2022-05-10
- Lead Sponsor
- International AIDS Vaccine Initiative
- Target Recruit Count
- 19
- Registration Number
- NCT03721510
- Locations
- 🇺🇸
Orlando Immunology Center, Orlando, Florida, United States
🇺🇸Center for Virology and Vaccine Research/ Clinical Trials Unit/ BIDMC, Boston, Massachusetts, United States
🇺🇸Houston AIDS Research Team (HART), Houston, Texas, United States
A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults
- Conditions
- HIV Infections
- First Posted Date
- 2018-10-09
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- International AIDS Vaccine Initiative
- Target Recruit Count
- 61
- Registration Number
- NCT03699241
- Locations
- 🇺🇸
MGH, Boston, Massachusetts, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇰🇪Kenya AIDS Vaccine Initiative, Nairobi, Kenya
A Phase I Trial to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer Vaccine, Adjuvanted
- Conditions
- HIV/AIDS
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2022-05-12
- Lead Sponsor
- International AIDS Vaccine Initiative
- Target Recruit Count
- 46
- Registration Number
- NCT03547245
- Locations
- 🇺🇸
George Washington University, Washington, District of Columbia, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence
- Conditions
- Tuberculosis, Pulmonary
- First Posted Date
- 2018-04-30
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- International AIDS Vaccine Initiative
- Target Recruit Count
- 831
- Registration Number
- NCT03512249
- Locations
- 🇿🇦
Task Clinical Research Centre, Bellville, Cape Town, South Africa
🇿🇦University of Cape Town Lung Institute, Mowbray, Cape Town, South Africa
🇿🇦The Aurum Institute: Tembisa Clinical Research Centre, Tembisa, Gauteng, South Africa
A Clinical Trial of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-infected and HIV-uninfected Adults
- Conditions
- HIV Infections
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2020-09-14
- Lead Sponsor
- International AIDS Vaccine Initiative
- Target Recruit Count
- 29
- Registration Number
- NCT03205917
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Safety, PK and Antiviral Activity of PGT121 Monoclonal Antibody in HIV-uninfected and HIV-infected Adults
- Conditions
- HIV Infection
- First Posted Date
- 2016-11-09
- Last Posted Date
- 2019-09-17
- Lead Sponsor
- International AIDS Vaccine Initiative
- Target Recruit Count
- 48
- Registration Number
- NCT02960581
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
MTBVAC Study in Adults With and Without Latent Tuberculosis Infection in South Africa
- Conditions
- Tuberculosis
- First Posted Date
- 2016-10-14
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- International AIDS Vaccine Initiative
- Target Recruit Count
- 144
- Registration Number
- NCT02933281
- Locations
- 🇿🇦
SATVI: Worcester, Worcester, South Africa
Trial of the Safety and Immunogenicity of an Oral, Replicating Ad26 Vectored HIV-1 Vaccine
- Conditions
- HIV
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2016-11-21
- Lead Sponsor
- International AIDS Vaccine Initiative
- Target Recruit Count
- 22
- Registration Number
- NCT02366013
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States